Investigation of frailty markers including a novel biomarker panel in emergency laparotomy: protocol of a prospective cohort study

Abstract Background Emergency laparotomy (EmLAP) is one of the commonest emergency operations performed in the United Kingdom (approximately 30, 000 laparotomies annually). These potentially high-risk procedures can be life changing with frail patients and/ or older adults (≥ 65 years) having the po...

Full description

Bibliographic Details
Main Authors: Hwei Jene Ng, Tara Quasim, Nicholas J. W. Rattray, Susan Moug
Format: Article
Language:English
Published: BMC 2023-07-01
Series:BMC Surgery
Subjects:
Online Access:https://doi.org/10.1186/s12893-023-02093-5
_version_ 1797784761578553344
author Hwei Jene Ng
Tara Quasim
Nicholas J. W. Rattray
Susan Moug
author_facet Hwei Jene Ng
Tara Quasim
Nicholas J. W. Rattray
Susan Moug
author_sort Hwei Jene Ng
collection DOAJ
description Abstract Background Emergency laparotomy (EmLAP) is one of the commonest emergency operations performed in the United Kingdom (approximately 30, 000 laparotomies annually). These potentially high-risk procedures can be life changing with frail patients and/ or older adults (≥ 65 years) having the poorest outcomes, including mortality. There is no gold standard of frailty assessment and no clinical chemical biomarkers existing in practice. Early detection of subclinical changes or deficits at the molecular level are essential in improving our understanding of the biology of frailty and ultimately improving patient outcomes. This study aims primarily to compare preoperative frailty markers, including a blood-based biomarker panel, in their ability to predict 30 and 90-day mortality post-EmLAP. The secondary aim is to analyse the influence of perioperative frailty on morbidity and quality of life post-EmLAP. Methods A prospective single centred observational study will be conducted on 150 patients ≥ 40 years of age that undergo EmLAP. Patients will be included according to the established NELA (National Emergency Laparotomy Audit) criteria. The variables collected include demographics, co-morbidities, polypharmacy, place of residence, indication and type of surgery (as per NELA criteria) and prognostic NELA score. Frailty will be assessed using: a blood sample for ultra-high performance liquid chromatography mass spectrometry analysis; preoperative CT abdomen pelvis (sarcopenia) and Rockwood Clinical Frailty Scale (CFS). Patients will be followed up for 90 days. Variables collected include blood samples (at post operative day 1, 7, 30 and 90), place of residence on discharge, morbidity, mortality and quality of life (EQ-5D-5 L). The frailty markers will be compared between groups of frail (CFS ≥ 4) and non-frail using statistical methods such as regression model and adjusted for appropriate confounding factors. Discussion This study hypothesises that frailty level changes following EmLAP in frail and non- frail patients, irrespective of age. We propose that non- frail patients will have better survival rates and report better quality of life compared to the frail. By studying the changes in metabolites/ biomarkers in these patients and correlate them to frailty status pre-surgery, this highly novel approach will develop new knowledge of frailty and define a new area of clinical biomolecular research. Trial registration ClinicalTrials.gov: NCT05416047. Registered on 13/06/2022 (retrospectively registered).
first_indexed 2024-03-13T00:45:27Z
format Article
id doaj.art-6225d2e812ef475ca60f0ef3f2a9d63d
institution Directory Open Access Journal
issn 1471-2482
language English
last_indexed 2024-03-13T00:45:27Z
publishDate 2023-07-01
publisher BMC
record_format Article
series BMC Surgery
spelling doaj.art-6225d2e812ef475ca60f0ef3f2a9d63d2023-07-09T11:04:52ZengBMCBMC Surgery1471-24822023-07-012311610.1186/s12893-023-02093-5Investigation of frailty markers including a novel biomarker panel in emergency laparotomy: protocol of a prospective cohort studyHwei Jene Ng0Tara Quasim1Nicholas J. W. Rattray2Susan Moug3School of Medical, Veterinary & Life Sciences (MVLS), University of GlasgowDepartment of Intensive Care Medicine, Glasgow Royal Infirmary, NHS Greater Glasgow and ClydeStrathclyde Institute of Pharmacy & Biomedical Sciences, University of StrathclydeDepartment of General Surgery, Royal Alexandra Hospital, NHS Greater Glasgow and ClydeAbstract Background Emergency laparotomy (EmLAP) is one of the commonest emergency operations performed in the United Kingdom (approximately 30, 000 laparotomies annually). These potentially high-risk procedures can be life changing with frail patients and/ or older adults (≥ 65 years) having the poorest outcomes, including mortality. There is no gold standard of frailty assessment and no clinical chemical biomarkers existing in practice. Early detection of subclinical changes or deficits at the molecular level are essential in improving our understanding of the biology of frailty and ultimately improving patient outcomes. This study aims primarily to compare preoperative frailty markers, including a blood-based biomarker panel, in their ability to predict 30 and 90-day mortality post-EmLAP. The secondary aim is to analyse the influence of perioperative frailty on morbidity and quality of life post-EmLAP. Methods A prospective single centred observational study will be conducted on 150 patients ≥ 40 years of age that undergo EmLAP. Patients will be included according to the established NELA (National Emergency Laparotomy Audit) criteria. The variables collected include demographics, co-morbidities, polypharmacy, place of residence, indication and type of surgery (as per NELA criteria) and prognostic NELA score. Frailty will be assessed using: a blood sample for ultra-high performance liquid chromatography mass spectrometry analysis; preoperative CT abdomen pelvis (sarcopenia) and Rockwood Clinical Frailty Scale (CFS). Patients will be followed up for 90 days. Variables collected include blood samples (at post operative day 1, 7, 30 and 90), place of residence on discharge, morbidity, mortality and quality of life (EQ-5D-5 L). The frailty markers will be compared between groups of frail (CFS ≥ 4) and non-frail using statistical methods such as regression model and adjusted for appropriate confounding factors. Discussion This study hypothesises that frailty level changes following EmLAP in frail and non- frail patients, irrespective of age. We propose that non- frail patients will have better survival rates and report better quality of life compared to the frail. By studying the changes in metabolites/ biomarkers in these patients and correlate them to frailty status pre-surgery, this highly novel approach will develop new knowledge of frailty and define a new area of clinical biomolecular research. Trial registration ClinicalTrials.gov: NCT05416047. Registered on 13/06/2022 (retrospectively registered).https://doi.org/10.1186/s12893-023-02093-5Emergency laparotomyFrailty biomarkersMass spectrometryClinical Frailty ScaleSarcopenia
spellingShingle Hwei Jene Ng
Tara Quasim
Nicholas J. W. Rattray
Susan Moug
Investigation of frailty markers including a novel biomarker panel in emergency laparotomy: protocol of a prospective cohort study
BMC Surgery
Emergency laparotomy
Frailty biomarkers
Mass spectrometry
Clinical Frailty Scale
Sarcopenia
title Investigation of frailty markers including a novel biomarker panel in emergency laparotomy: protocol of a prospective cohort study
title_full Investigation of frailty markers including a novel biomarker panel in emergency laparotomy: protocol of a prospective cohort study
title_fullStr Investigation of frailty markers including a novel biomarker panel in emergency laparotomy: protocol of a prospective cohort study
title_full_unstemmed Investigation of frailty markers including a novel biomarker panel in emergency laparotomy: protocol of a prospective cohort study
title_short Investigation of frailty markers including a novel biomarker panel in emergency laparotomy: protocol of a prospective cohort study
title_sort investigation of frailty markers including a novel biomarker panel in emergency laparotomy protocol of a prospective cohort study
topic Emergency laparotomy
Frailty biomarkers
Mass spectrometry
Clinical Frailty Scale
Sarcopenia
url https://doi.org/10.1186/s12893-023-02093-5
work_keys_str_mv AT hweijeneng investigationoffrailtymarkersincludinganovelbiomarkerpanelinemergencylaparotomyprotocolofaprospectivecohortstudy
AT taraquasim investigationoffrailtymarkersincludinganovelbiomarkerpanelinemergencylaparotomyprotocolofaprospectivecohortstudy
AT nicholasjwrattray investigationoffrailtymarkersincludinganovelbiomarkerpanelinemergencylaparotomyprotocolofaprospectivecohortstudy
AT susanmoug investigationoffrailtymarkersincludinganovelbiomarkerpanelinemergencylaparotomyprotocolofaprospectivecohortstudy